Whereas expression of aIIb is specific to the megakaryocyte lineage, b3 has a widespread tissue distribution as part of the vitronectin receptor (avb3). Despite the wider expression of the b3 subunit, the bleeding phenotype continues to dominate for ITGB3 mutations. In rare patients, gain-of-function mutations in either ITGA2B or ITGB3 can also interfere with megakaryocytopoiesis and lead to platelet anisocytosis and moderate thrombocytopenia. 3 
Analytical methods
The anucleate platelet contains low amounts of RNA that is often unstable; therefore, mutation screening in GT is largely based on DNA analysis. A range of DNA screening methods have been described, including PCR single-strand conformation polymorphism analysis and denaturing gradient gel electrophoresis. 4 More recently, highresolution melting (HRM) screening has been used. 5 Nonetheless, none of these methods are 100% guaranteed, and standard PCR of genomic DNA followed by direct sequencing of essential coding and flanking regions of both ITGA2B and ITGB3 is recommended.
Analytical validation
Analyses of mutated and non-mutated control samples are recommended. Quality control is also important, particularly for DNA isolated in different laboratories. Both strands of DNA should be sequenced and variations confirmed by an independent method (eg, restriction enzyme analysis, ASA-PCR; HRM and so on) and/ or by DNA sequencing of a second sample. 5 Identified variations can be directly compared with available databases and bioinformatic softwares, to establish whether they correspond to known mutations and to assess their potential pathological nature. Transmission of the mutation(s) should be established by analysis of family members whenever possible. Molecular modeling on the basis of the known crystal structure of the aIIbb3 and avb3 extracellular domains can help to assess the effect of missense mutations on integrin structure. 6, 7 Expression of recombinant mutated integrin in heterologous cell lines can be informative on expression and function, but is only available on a research basis in specialized laboratories. RT-PCR may be used to confirm potential splicing defects of RNA expression. Large deletions may be looked for by quantitative multiplex fluorescence-PCR, especially when standard DNA sequencing reveals a single heterozygous mutation in a patient with a clear GT phenotype.
1.8 Estimated frequency of the disease (incidence at birth ('birth prevalence') or population prevalence) Unknown. No epidemiological data are currently available for GT on a world-wide basis. 8 It is more common in Europe and the Middle East than in the United States, and is clustered within certain ethnic groups (see below). In France, a recent census suggests approximately 300 cases, half of whom are of Manouche Gypsy origin and share the same mutation (M Fiore, data not published).
1.9 If applicable, prevalence in the ethnic group of investigated persons GT occurs in high frequency in certain ethnic populations, with an increased incidence of consanguinity, such as Iraqi Jews, Palestinian Arabs or Jordanian Arabs. 9, 10 The unusual high frequency of GT among these groups is largely the result of founder mutations. In France, GT is particularly frequent in the Gypsy population, mainly represented by the Manouche tribe, with a founder mutation estimated by us to have occurred 300-400 years ago. 11
Diagnostic setting
Yes No
A. Although very rare, acquired thrombasthenia has been reported in leukemia with chromosome 15-17 translocations; it is more commonly associated with autoantibodies directed against aIIbb3, some of which also induce thrombocytopenia, as well as blocking aIIbb3 function. 12, 13 It is also to be noted that some anti-thrombotic therapies involve the use of aIIbb3-blocking drugs that transiently induce a GT-like state.
In leukocyte adhesion deficiency-3, patients manifest a bleeding phenotype with immune deficiency and recurrent infections, but demonstrate a normal expression of b3 integrins. Mutations in the FERMT3 gene (encoding kindlin-3) account for the phenotype. 14 Kindlin-3 belongs to a family of proteins that cooperate in integrin activation. 3 Platelet aggregation defects restricted to specific agonists may imply abnormalities of a signaling pathway and should be distinguished from GT, where aggregation is defective for all physiological agonists in the presence of a normal platelet number and size. GPIb-related function as assessed by ristocetin-induced platelet agglutination is normal, although it can be cyclic. B. To date, studies have failed to find any correlation between frequency and severity of bleeding and the nature of the gene defect in GT. Bleeding tendencies can differ considerably between affected persons, even within the same family or ethnic group. 3 C. Mutation screening in patients and family members is essential for genetic counseling, for most patients will have their own private mutation (unless in an ethnic group). DNA analysis allows identification of asymptomatic heterozygous carriers, as these cannot be identified with certainty by phenotypic studies alone. 4 Expression of aIIbb3 in platelets of normal healthy subjects is known to vary by more than two-fold. 
TEST CHARACTERISTICS
Negative C D Positive predictive value: Negative predictive value:
2.1 Analytical sensitivity (proportion of positive tests if the genotype is present) For cases with a classic GT phenotype, the success of mutation analysis by DNA sequencing of ITGA2B and ITGB3 ranges from 80 to 90%. Other possible causes of GT, such as miRNAs and intronic mutations, are not currently researched, although an involvement of other genes (eg, chaperone defects) cannot be ruled out. Once a mutation is found the success of genotyping should be 100%.
Analytical specificity (proportion of negative tests if the genotype is not present)
Genetic testing is expected to be negative in the absence of the disease with a specificity of 100%. However, both aIIb and b3 are polymorphic glycoproteins, so that each new amino acid substitution has to have its pathogenicity proven (or non-proven).
Clinical sensitivity (proportion of positive tests if the disease is present)
The clinical sensitivity can be dependent on variable factors, such as age or family history. In such cases, a general statement should be given, even if a quantification can only be made case by case. A sensitivity of 100% for patients with a classical GT phenotype of the disorder (absence of platelet aggregation and aIIbb3 expression) can be achieved. However, some mutations may only partially block integrin expression/function, and consequently the bleeding syndrome can be negligible. In such cases, the characterization of aIIbb3 may require specialized procedures. The clinical severity of GT tends to diminish with age, although the bleeding manifestations persist and are life-long.
Clinical specificity (proportion of negative tests if the disease is not present)
The clinical specificity can be dependent on variable factors, such as age or family history. In such cases, a general statement should be given, even if a quantification can only be made case by case.
In the absence of GT the proportion of negative tests is expected to be high, although the prevalence of other disorders interfering with platelet function is relatively high, and mucocutaneous bleeding is symptomatic for all of them.
Positive clinical predictive value (life-time risk of developing the disease if the test is positive)
Not applicable. GT shows complete penetrance, and most patients are diagnosed at birth or during early infancy. 2 
Negative clinical predictive value (probability of not developing the disease if the test is negative)
If an index case has been genotyped negatively (with normal platelet function and full aIIbb3 expression), the probability of not developing the disease by the propositus and other family members is 100%.
Even if an index case in a given family has not been tested genetically, phenotypic characterization can exclude the diagnosis in 100% of family members. However, this is not the case if members of the family have another bleeding disorder. In such a case, genetic analysis is indispensable. Platelet function testing 3.1.2 Describe the burden of alternative diagnostic methods to the patient GT is readily identifiable by platelet function testing, and a lack of platelet aggregation in response to all physiological agonists, such as ADP, collagen, epinephrine or thrombin, is unique for this disease. Clot retraction is also abnormal for most patients with GT. Flow cytometry allows rapid identification of both aIIbb3 deficiency and (with specific tests) non-functional aIIbb3. 1 These provide minimal inconvenience to the patient and can be performed with 10-30 ml blood. However, only DNA analysis can confirm that the disease is caused by a genetic defect.
CLINICAL UTILITY

How is the cost effectiveness of alternative diagnostic methods to be judged?
There are no studies available to determine the cost effectiveness of alternative diagnostic approaches to GT. Nevertheless, biological analyses have to be performed in a specialized laboratory and their cost effectiveness is high. Moreover, platelet samples must be processed and analyzed within 4 h of blood collection, which is not always possible when they are sent from far away. So, often the patient has to visit a specialized center. In contrast, samples for DNA testing can be sent by mail.
Will disease management be influenced by the result of a genetic test?
No &
Yes 2 Therapy (please describe)
The genetic test will confirm the suspected diagnosis although in the majority of cases treatment will remain the same. Generally, in GT, local measures will control nasal and superficial bleeding, whereas platelet transfusions are used to control or prevent life-threatening blood loss. 15, 16 Severe bleeding can be spontaneous or trauma-related. Gastrointestinal bleeding is a frequent problem. Treatment of the bleeding by platelet transfusion can become ineffective due to naturally occurring antibodies directed against aIIbb3. 17, 18 Such antibodies are produced when the patient's immune system comes into contact with normal platelets (after transfusion, pregnancy). Activated recombinant factor VII (rFVIIa) provides an alternative treatment for GT patients who develop such antibodies. 19 Patients with mutations causing absence or premature termination of aIIb or b3 are particularly prone to form antibodies against aIIbb3. 20 This finding may help in deciding whether platelet transfusion or rFVIIa should be used. There is no evidence as yet that knowing the mutation will affect prognosis or management of the disease although the choice of therapy may be influenced by the presence of inhibitors. 
Predictive
IF APPLICABLE, FURTHER CONSEQUENCES OF TESTING
Please assume that the result of a genetic test has no immediate medical consequences. Is there any evidence that a genetic test is nevertheless useful for the patient or his/her relatives? (Please describe) Diagnosis of GT is based first on the clinical and phenotypic characterization, including specific biological studies designed to assess quantitative and qualitative deficiencies of aIIbb3. Biological testing originally resulted in the classification of GT into three subtypes: type I with little or no expression of aIIbb3, no fibrinogen in a-granules and no clot retraction; type II with 5 to 20% aIIbb3, and as a consequence, fibrinogen in a-granules and a subnormal to normal clot retraction; and variant GT with 50% or more of the normal expression of aIIbb3 unable to support aggregation. 2 Nonetheless, genetic testing should be proposed to families because: (i) a positive test helps to remove any doubt in the diagnosis; (ii) it is essential for carrier detection; the asymptomatic carriers display a normal phenotype; and (iii) in some cases, it may be useful for prediction of anti-platelet antibody formation. Genetic testing also provides more precise information on the cause of the aIIbb3 deficiency or non-functioning.
